Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 540

1.

Reminiscences on the "Classic" 1976 FRAP Article in Biophysical Journal.

Axelrod D, Elson EL, Schlessinger J, Koppel DE.

Biophys J. 2018 Sep 4. pii: S0006-3495(18)31014-2. doi: 10.1016/j.bpj.2018.08.037. [Epub ahead of print] No abstract available.

PMID:
30224052
2.

Self-reported Patient Motivations for Seeking Cosmetic Procedures.

Maisel A, Waldman A, Furlan K, Weil A, Sacotte K, Lazaroff JM, Lin K, Aranzazu D, Avram MM, Bell A, Cartee TV, Cazzaniga A, Chapas A, Crispin MK, Croix JA, DiGiorgio CM, Dover JS, Goldberg DJ, Goldman MP, Green JB, Griffin CL, Haimovic AD, Hausauer AK, Hernandez SL, Hsu S, Ibrahim O, Jones DH, Kaufman J, Kilmer SL, Lee NY, McDaniel DH, Schlessinger J, Tanzi E, Weiss ET, Weiss RA, Wu D, Poon E, Alam M.

JAMA Dermatol. 2018 Aug 15. doi: 10.1001/jamadermatol.2018.2357. [Epub ahead of print]

PMID:
30140900
3.

A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers.

Gettinger SN, Choi J, Mani N, Sanmamed MF, Datar I, Sowell R, Du VY, Kaftan E, Goldberg S, Dong W, Zelterman D, Politi K, Kavathas P, Kaech S, Yu X, Zhao H, Schlessinger J, Lifton R, Rimm DL, Chen L, Herbst RS, Schalper KA.

Nat Commun. 2018 Aug 10;9(1):3196. doi: 10.1038/s41467-018-05032-8.

4.

Identification of a biologically active fragment of ALK and LTK-Ligand 2 (augmentor-α).

Reshetnyak AV, Mohanty J, Tomé F, Puleo DE, Plotnikov AN, Ahmed M, Kaur N, Poliakov A, Cinnaiyan AM, Lax I, Schlessinger J.

Proc Natl Acad Sci U S A. 2018 Aug 14;115(33):8340-8345. doi: 10.1073/pnas.1807881115. Epub 2018 Jul 30.

PMID:
30061385
5.

Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer.

Bonazzoli E, Predolini F, Cocco E, Bellone S, Altwerger G, Menderes G, Zammataro L, Bianchi A, Pettinella F, Riccio F, Han C, Yadav G, Lopez S, Manzano A, Manara P, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Schlessinger J, Santin AD.

Clin Cancer Res. 2018 Jun 25. doi: 10.1158/1078-0432.CCR-18-0864. [Epub ahead of print]

PMID:
29941483
6.

Safety and efficacy of hydrogen peroxide topical solution, 40% (w/w) in patients with seborrheic keratoses: results from two identical, randomized, double-blind, placebo-controlled, phase 3 studies (A-101-SEBK-301/302).

Baumann LS, Blauvelt A, Draelos ZD, Kempers SE, Lupo MP, Schlessinger J, Smith SR, Wilson DC, Bradshaw M, Estes E, Shanler SD.

J Am Acad Dermatol. 2018 Jun 1. pii: S0190-9622(18)30841-7. doi: 10.1016/j.jaad.2018.05.044. [Epub ahead of print]

7.

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.

Kadara H, Choi M, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Yoo Y, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Wistuba II, Herbst RS.

Ann Oncol. 2018 Apr 1;29(4):1072. doi: 10.1093/annonc/mdx062. No abstract available.

PMID:
29688333
8.

Efficacy and Safety of ATX-101 by Treatment Session: Pooled Analysis of Data From the Phase 3 REFINE Trials.

Dayan SH, Schlessinger J, Beer K, Donofrio LM, Jones DH, Humphrey S, Carruthers J, Lizzul PF, Gross TM, Beddingfield FC 3rd, Somogyi C.

Aesthet Surg J. 2018 Aug 16;38(9):998-1010. doi: 10.1093/asj/sjy008.

9.

Structures of β-klotho reveal a 'zip code'-like mechanism for endocrine FGF signalling.

Lee S, Choi J, Mohanty J, Sousa LP, Tome F, Pardon E, Steyaert J, Lemmon MA, Lax I, Schlessinger J.

Nature. 2018 Jan 25;553(7689):501-505. doi: 10.1038/nature25010. Epub 2018 Jan 17.

PMID:
29342135
10.
11.

Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies.

Pariser D, Frankel E, Schlessinger J, Poulin Y, Vender R, Langley RG, Meng X, Guana A, Nyirady J.

Dermatol Ther (Heidelb). 2018 Mar;8(1):17-32. doi: 10.1007/s13555-017-0211-4. Epub 2017 Dec 7.

12.

Acne, Vulgaris.

Sutaria AH, Schlessinger J.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-.
2017 Oct 15.

13.

Chloracne.

Schlessinger DI, Schlessinger J.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-.
2017 Oct 15.

14.

Alk and Ltk ligands are essential for iridophore development in zebrafish mediated by the receptor tyrosine kinase Ltk.

Mo ES, Cheng Q, Reshetnyak AV, Schlessinger J, Nicoli S.

Proc Natl Acad Sci U S A. 2017 Nov 7;114(45):12027-12032. doi: 10.1073/pnas.1710254114. Epub 2017 Oct 23.

15.

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.

Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, Du VY, Schlessinger J, Goldberg SB, Chiang A, Sanmamed MF, Melero I, Agorreta J, Montuenga LM, Lifton R, Ferrone S, Kavathas P, Rimm DL, Kaech SM, Schalper K, Herbst RS, Politi K.

Cancer Discov. 2017 Dec;7(12):1420-1435. doi: 10.1158/2159-8290.CD-17-0593. Epub 2017 Oct 12.

PMID:
29025772
16.

Urticaria, Solar.

Badri T, Schlessinger J.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-.
2017 Jun 27.

17.

Identification and Characterization of JAK2 Pseudokinase Domain Small Molecule Binders.

Puleo DE, Kucera K, Hammarén HM, Ungureanu D, Newton AS, Silvennoinen O, Jorgensen WL, Schlessinger J.

ACS Med Chem Lett. 2017 May 17;8(6):618-621. doi: 10.1021/acsmedchemlett.7b00153. eCollection 2017 Jun 8.

18.

JAK2 JH2 Fluorescence Polarization Assay and Crystal Structures for Complexes with Three Small Molecules.

Newton AS, Deiana L, Puleo DE, Cisneros JA, Cutrona KJ, Schlessinger J, Jorgensen WL.

ACS Med Chem Lett. 2017 May 17;8(6):614-617. doi: 10.1021/acsmedchemlett.7b00154. eCollection 2017 Jun 8.

19.

New Uses of AbobotulinumtoxinA in Aesthetics.

Schlessinger J, Gilbert E, Cohen JL, Kaufman J.

Aesthet Surg J. 2017 May 1;37(suppl_1):S45-S58. doi: 10.1093/asj/sjx005. Review.

20.

Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function.

Choi M, Kadara H, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Kim K, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Herbst RS, Wistuba II.

Ann Oncol. 2017 Jan 1;28(1):83-89. doi: 10.1093/annonc/mdw437.

PMID:
28177435
21.

Split-Face Comparison of an Advanced Non-Hydroquinone Lightening Solution to 4% Hydroquinone.

Schlessinger J, Saxena S, Mohr S.

J Drugs Dermatol. 2016 Dec 1;15(12):1571-1577.

PMID:
28095580
22.

Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.

Zhao S, Bellone S, Lopez S, Thakral D, Schwab C, English DP, Black J, Cocco E, Choi J, Zammataro L, Predolini F, Bonazzoli E, Bi M, Buza N, Hui P, Wong S, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Odicino F, Pecorelli S, Donzelli C, Ardighieri L, Facchetti F, Falchetti M, Silasi DA, Ratner E, Azodi M, Schwartz PE, Mane S, Angioli R, Terranova C, Quick CM, Edraki B, Bilgüvar K, Lee M, Choi M, Stiegler AL, Boggon TJ, Schlessinger J, Lifton RP, Santin AD.

Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):12238-12243. Epub 2016 Oct 10.

23.

7th Annual Cosmetic Surgery Forum 2015.

Schlessinger J.

Skinmed. 2016 Aug 1;14(4):297-299. eCollection 2016. No abstract available.

PMID:
27784522
24.

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.

Kadara H, Choi M, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Yoo Y, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Wistuba II, Herbst RS.

Ann Oncol. 2017 Jan 1;28(1):75-82. doi: 10.1093/annonc/mdw436.

25.

Regression of Chemotherapy-Resistant Polymerase ε (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab.

Santin AD, Bellone S, Buza N, Choi J, Schwartz PE, Schlessinger J, Lifton RP.

Clin Cancer Res. 2016 Dec 1;22(23):5682-5687. Epub 2016 Aug 2.

26.

Distinct cellular properties of oncogenic KIT receptor tyrosine kinase mutants enable alternative courses of cancer cell inhibition.

Shi X, Sousa LP, Mandel-Bausch EM, Tome F, Reshetnyak AV, Hadari Y, Schlessinger J, Lax I.

Proc Natl Acad Sci U S A. 2016 Aug 16;113(33):E4784-93. doi: 10.1073/pnas.1610179113. Epub 2016 Aug 1.

27.

Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-β-dependent mechanisms.

Shi X, Mihaylova VT, Kuruvilla L, Chen F, Viviano S, Baldassarre M, Sperandio D, Martinez R, Yue P, Bates JG, Breckenridge DG, Schlessinger J, Turk BE, Calderwood DA.

Proc Natl Acad Sci U S A. 2016 Aug 2;113(31):E4558-66. doi: 10.1073/pnas.1608319113. Epub 2016 Jul 18.

28.

Assessment of a Novel Anti-Aging Hand Cream.

Schlessinger J, Saxena S, Mohr S.

J Drugs Dermatol. 2016 Apr;15(4):496-503.

PMID:
27050706
29.

The Dark Side of Cell Signaling: Positive Roles for Negative Regulators.

Lemmon MA, Freed DM, Schlessinger J, Kiyatkin A.

Cell. 2016 Mar 10;164(6):1172-1184. doi: 10.1016/j.cell.2016.02.047. Review.

30.

Data publication with the structural biology data grid supports live analysis.

Meyer PA, Socias S, Key J, Ransey E, Tjon EC, Buschiazzo A, Lei M, Botka C, Withrow J, Neau D, Rajashankar K, Anderson KS, Baxter RH, Blacklow SC, Boggon TJ, Bonvin AM, Borek D, Brett TJ, Caflisch A, Chang CI, Chazin WJ, Corbett KD, Cosgrove MS, Crosson S, Dhe-Paganon S, Di Cera E, Drennan CL, Eck MJ, Eichman BF, Fan QR, Ferré-D'Amaré AR, Fromme JC, Garcia KC, Gaudet R, Gong P, Harrison SC, Heldwein EE, Jia Z, Keenan RJ, Kruse AC, Kvansakul M, McLellan JS, Modis Y, Nam Y, Otwinowski Z, Pai EF, Pereira PJ, Petosa C, Raman CS, Rapoport TA, Roll-Mecak A, Rosen MK, Rudenko G, Schlessinger J, Schwartz TU, Shamoo Y, Sondermann H, Tao YJ, Tolia NH, Tsodikov OV, Westover KD, Wu H, Foster I, Fraser JS, Maia FR, Gonen T, Kirchhausen T, Diederichs K, Crosas M, Sliz P.

Nat Commun. 2016 Mar 7;7:10882. doi: 10.1038/ncomms10882.

31.

Nuclear magnetic resonance analysis of the conformational state of cancer mutant of fibroblast growth factor receptor 1 tyrosine kinase domain.

Kobashigawa Y, Amano S, Yoza K, Himeno R, Amemiya S, Morioka H, Yokogawa M, Kumeta H, Schlessinger J, Inagaki F.

Genes Cells. 2016 Apr;21(4):350-7. doi: 10.1111/gtc.12345. Epub 2016 Feb 10.

32.

Early and multiple origins of metastatic lineages within primary tumors.

Zhao ZM, Zhao B, Bai Y, Iamarino A, Gaffney SG, Schlessinger J, Lifton RP, Rimm DL, Townsend JP.

Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):2140-5. doi: 10.1073/pnas.1525677113. Epub 2016 Feb 8.

33.

A Firming Neck Cream Containing N-Acetyl Glucosamine Significantly Improves Signs of Aging on the Challenging Neck and Décolletage.

Schlessinger J, Green B, Edison BL, Murphy L, Sabherwal Y.

J Drugs Dermatol. 2016 Jan;15(1):47-52.

PMID:
26741381
34.

Augmentor α and β (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand-receptor interactions.

Reshetnyak AV, Murray PB, Shi X, Mo ES, Mohanty J, Tome F, Bai H, Gunel M, Lax I, Schlessinger J.

Proc Natl Acad Sci U S A. 2015 Dec 29;112(52):15862-7. doi: 10.1073/pnas.1520099112. Epub 2015 Nov 16.

35.

Inhibition of ErbB3 by a monoclonal antibody that locks the extracellular domain in an inactive configuration.

Lee S, Greenlee EB, Amick JR, Ligon GF, Lillquist JS, Natoli EJ Jr, Hadari Y, Alvarado D, Schlessinger J.

Proc Natl Acad Sci U S A. 2015 Oct 27;112(43):13225-30. doi: 10.1073/pnas.1518361112. Epub 2015 Oct 12.

36.

Structural analysis of the mechanism of phosphorylation of a critical autoregulatory tyrosine residue in FGFR1 kinase domain.

Kobashigawa Y, Amano S, Yokogawa M, Kumeta H, Morioka H, Inouye M, Schlessinger J, Inagaki F.

Genes Cells. 2015 Oct;20(10):860-70. doi: 10.1111/gtc.12277. Epub 2015 Aug 24.

37.

Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.

Krauthammer M, Kong Y, Bacchiocchi A, Evans P, Pornputtapong N, Wu C, McCusker JP, Ma S, Cheng E, Straub R, Serin M, Bosenberg M, Ariyan S, Narayan D, Sznol M, Kluger HM, Mane S, Schlessinger J, Lifton RP, Halaban R.

Nat Genet. 2015 Sep;47(9):996-1002. doi: 10.1038/ng.3361. Epub 2015 Jul 27.

38.

Improved survival of patients with hypermutation in uterine serous carcinoma.

Santin AD, Bellone S, Centritto F, Schlessinger J, Lifton R.

Gynecol Oncol Rep. 2015 Jan 24;12:3-4. doi: 10.1016/j.gore.2015.01.005. eCollection 2015 Apr.

39.

FGF1 and FGF19 reverse diabetes by suppression of the hypothalamic-pituitary-adrenal axis.

Perry RJ, Lee S, Ma L, Zhang D, Schlessinger J, Shulman GI.

Nat Commun. 2015 Apr 28;6:6980. doi: 10.1038/ncomms7980.

40.

Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK.

Murray PB, Lax I, Reshetnyak A, Ligon GF, Lillquist JS, Natoli EJ Jr, Shi X, Folta-Stogniew E, Gunel M, Alvarado D, Schlessinger J.

Sci Signal. 2015 Jan 20;8(360):ra6. doi: 10.1126/scisignal.2005916.

PMID:
25605972
41.

The strength and cooperativity of KIT ectodomain contacts determine normal ligand-dependent stimulation or oncogenic activation in cancer.

Reshetnyak AV, Opatowsky Y, Boggon TJ, Folta-Stogniew E, Tome F, Lax I, Schlessinger J.

Mol Cell. 2015 Jan 8;57(1):191-201. doi: 10.1016/j.molcel.2014.11.021. Epub 2014 Dec 24.

42.

Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma.

Juhlin CC, Goh G, Healy JM, Fonseca AL, Scholl UI, Stenman A, Kunstman JW, Brown TC, Overton JD, Mane SM, Nelson-Williams C, Bäckdahl M, Suttorp AC, Haase M, Choi M, Schlessinger J, Rimm DL, Höög A, Prasad ML, Korah R, Larsson C, Lifton RP, Carling T.

J Clin Endocrinol Metab. 2015 Mar;100(3):E493-502. doi: 10.1210/jc.2014-3282. Epub 2014 Dec 9.

43.

Safety and efficacy of calcipotriene plus betamethasone dipropionate topical suspension in the treatment of extensive scalp psoriasis in adolescents ages 12 to 17 years.

Eichenfield LF, Ganslandt C, Kurvits M, Schlessinger J.

Pediatr Dermatol. 2015 Jan-Feb;32(1):28-35. doi: 10.1111/pde.12429. Epub 2014 Nov 21.

44.

Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities.

Lew ED, Oh J, Burrola PG, Lax I, Zagórska A, Través PG, Schlessinger J, Lemke G.

Elife. 2014 Sep 29;3. doi: 10.7554/eLife.03385.

45.

The docking protein FRS2α is a critical regulator of VEGF receptors signaling.

Chen PY, Qin L, Zhuang ZW, Tellides G, Lax I, Schlessinger J, Simons M.

Proc Natl Acad Sci U S A. 2014 Apr 15;111(15):5514-9. doi: 10.1073/pnas.1404545111. Epub 2014 Apr 2.

46.

The EGFR family: not so prototypical receptor tyrosine kinases.

Lemmon MA, Schlessinger J, Ferguson KM.

Cold Spring Harb Perspect Biol. 2014 Apr 1;6(4):a020768. doi: 10.1101/cshperspect.a020768. Review.

47.

Receptor tyrosine kinases: legacy of the first two decades.

Schlessinger J.

Cold Spring Harb Perspect Biol. 2014 Mar 1;6(3). pii: a008912. doi: 10.1101/cshperspect.a008912. Review.

48.

Structure, domain organization, and different conformational states of stem cell factor-induced intact KIT dimers.

Opatowsky Y, Lax I, Tomé F, Bleichert F, Unger VM, Schlessinger J.

Proc Natl Acad Sci U S A. 2014 Feb 4;111(5):1772-7. doi: 10.1073/pnas.1323254111. Epub 2014 Jan 21.

49.

Long-term safety of abobotulinumtoxinA for the treatment of glabellar lines: results from a 36-month, multicenter, open-label extension study.

Schlessinger J, Dover JS, Joseph J, Monheit G, Nelson DB, Albright CD, Axford-Gatley RA, Cohen JL; Dysport Study Group.

Dermatol Surg. 2014 Feb;40(2):176-83. doi: 10.1111/dsu.12404. Epub 2013 Dec 26.

PMID:
24372978
50.

Tony Pawson (1952-2013).

Schlessinger J.

Cancer Cell. 2013 Sep 9;24(3):273-4. No abstract available.

Supplemental Content

Loading ...
Support Center